Recent Updates
Recently added Catalysts
AZN Positive Sentiment

Omniose Announces Its Acquisition by AstraZeneca

Tuesday, November 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: AstraZeneca has acquired preclinical biotech firm Omniose, integrating it as a wholly owned subsidiary within its Infectious Disease Unit. This move concludes a productive three-year exclusive research collaboration between the two entities. The deal brings Omniose’s proprietary bioconjugation platform and specialized expertise directly into AstraZeneca’s operations. This acquisition aims to complement AstraZeneca's existing capabilities in infectious disease research and development.

Market Sentiment Analysis

POSITIVE FACTORS

  • Omniose has been acquired by AstraZeneca.
  • The acquisition follows a successful three-year collaboration.
  • Omniose's bioconjugation platform enhances AstraZeneca's capabilities.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+22%
120-day peak, hindsight
Typical move
1.2%
average across 15 past catalysts
Lead asset
Elecoglipron
Phase 3 · Heart Failure With Preserved Ejection Fraction (HFpEF)

Full Press Release Details

ST. LOUIS--(BUSINESS WIRE)--Omniose, a preclinical biotechnology company, today announced that it has been acquired by AstraZeneca. The acquisition follows a productive three-year exclusive research collaboration with AstraZeneca.Under the terms of the agreement, Omniose has become a wholly owned subsidiary of AstraZeneca and a part of the Infectious Disease Unit. The acquisition brings Omniose’s proprietary bioconjugation platform and expertise into AstraZeneca, complementing existing capabilit

Frequently Asked Questions

Who acquired Omniose?

AstraZeneca acquired Omniose, making it a wholly owned subsidiary.

What preceded the deal?

The acquisition followed a productive three-year exclusive research collaboration.

Where does Omniose fit?

Omniose joins AstraZeneca's Infectious Disease Unit as part of the deal.

What technology is involved?

AstraZeneca gains Omniose's proprietary bioconjugation platform and related expertise.

ShareAdd on Google
Tags: AZN Omniose AstraZeneca bioconjugation Infectious Disease acquisition
Last updated: Nov 10, 2026

Biotech snapshot

Lead asset
ElecoglipronPhase 3
Heart Failure With Preserved Ejection Fraction (HFpEF) →

Catalyst track record

+22%
best trade around AZN's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for AZN.

See every catalyst's timing & PoA →